The latest price target for Trevi Therapeutics (NASDAQ:TRVI) was reported by HC Wainwright & Co. on January 9, 2026. The analyst firm set a price target for $21.00 expecting TRVI to rise to within 12 months (a possible 55.56% upside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Trevi Therapeutics (NASDAQ:TRVI) was provided by HC Wainwright & Co., and Trevi Therapeutics reiterated their buy rating.

The last upgrade for Trevi Therapeutics Inc happened on March 10, 2025 when Raymond James raised their price target to $29. Raymond James previously had an outperform for Trevi Therapeutics Inc.

There is no last downgrade for Trevi Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trevi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trevi Therapeutics was filed on January 9, 2026 so you should expect the next rating to be made available sometime around January 9, 2027.

While ratings are subjective and will change, the latest Trevi Therapeutics (TRVI) rating was a reiterated with a price target of $21.00 to $21.00. The current price Trevi Therapeutics (TRVI) is trading at is $13.50, which is out of the analyst’s predicted range.